News Alector, Inc.

Stocks

ALEC

US0144421072

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 14:45:26 2026-10-07 EDT			5-day change	1st Jan Change
1.895 ^USD	+4.70%		+0.81%	+19.55%

10-05	Alector Shares Rise After Licensing AL050 Program to Roche's Genentech	MT
10-05	Alector, Inc. And Genentech, Inc. Enter Global License Agreement For Brain Penetrant GCase Enzyme Replacement Therapy For Parkinsons Disease And Other Neurodegenerative Diseases	CI

All News

Mentions Relevance

10-05	Alector Shares Rise After Licensing AL050 Program to Roche's Genentech	MT
10-05	Alector, Inc. And Genentech, Inc. Enter Global License Agreement For Brain Penetrant GCase Enzyme Replacement Therapy For Parkinsons Disease And Other Neurodegenerative Diseases	CI
10-05	Alector Licenses AL050 Program to Roche's Genentech	MT
10-05	Alector Enters Global License Agreement with Genentech for Brain Penetrant GCase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases	GL
09-15	Alector, Inc. Presents at Morgan Stanley 24th Annual Global Healthcare Conference, Sep-15-2026 07:00 AM
09-15	Alector, Inc. Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference, Sep-10-2026 02:10 PM
09-03	Alector to Participate in Upcoming Healthcare Conferences	GL
08-06	Alector : Quarterly Report for Quarter Ending June 30, 2026 (Form 10-Q)	PU
08-06	Alector: Q2 Earnings Snapshot	AQ
08-06	Alector, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-06	Alector Reports Second Quarter 2026 Financial Results and Provides Business Update	GL
07-08	Alector and GSK partnership to end after dementia, Alzheimer's drug failures	RE
07-08	Alector, Inc. Announces Termination of Collaboration Agreement with Glaxo Wellcome UK Limited	CI
07-08	Alector LLC and Alector, Inc. Repay $10,428,827.77 Aggregate Principal Amount Of Loans Under Loan And Security Agreement With Hercules Capital, Inc	CI
05-07	Alector : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
05-07	Alector: Q1 Earnings Snapshot	AQ
05-07	Alector, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-07	Alector Reports First Quarter 2026 Financial Results and Provides Business Update	GL
05-05	Alector, Inc. - Special Call
04-29	Alector to discontinue phase 2 trial of nivisnebart	RE
04-29	Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer’s Disease Following Interim Futility Analysis	GL
04-29	Alector Inc Discontinues Phase 2 Progress-Ad Trial of Nivisnebart and Provides Pipeline Update	CI
04-15	Alector Shares Rise After Cantor Fitzgerald Upgrade	MT
04-15	Cantor Fitzgerald Upgrades Alector to Overweight From Neutral	MT
03-25	Alector : March 2026 Corporate Presentation	PU